» Authors » George R Thompson

George R Thompson

Explore the profile of George R Thompson including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 50
Citations 1741
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Wiederhold N, Patterson H, Ferrer D, Garcia V, Thompson G, Patterson T
Antimicrob Agents Chemother . 2024 Nov; 69(1):e0098824. PMID: 39570032
We evaluated the activity of olorofim against species. Olorofim demonstrated potent activity against all isolates tested with a minimum inhibitory concentration (MIC) range ≤0.008-0.06 µg/mL and geometric mean MIC of...
2.
Honore P, Bassetti M, Cornely O, Dupont H, Fortun J, Kollef M, et al.
Crit Care . 2024 Nov; 28(1):361. PMID: 39529079
Background: Invasive candidiasis/candidemia (IC/C) is associated with a substantial health economic burden driven primarily by prolonged hospital stay. The once-weekly IV echinocandin, rezafungin acetate, has demonstrated non-inferiority to caspofungin in...
3.
Harding A, Crossen A, Reedy J, Basham K, Hepworth O, Zhang Y, et al.
bioRxiv . 2024 Sep; PMID: 39314271
Respiratory fungal infections pose a significant threat to human health. Animal models do not fully recapitulate human disease, necessitating advanced models to study human-fungal pathogen interactions. In this study, we...
4.
Savage H, Bays D, Tiffany C, Gonzalez M, Bejarano E, Carvalho T, et al.
Cell Host Microbe . 2024 Jun; 32(7):1103-1113.e6. PMID: 38838675
Antibiotic treatment promotes the outgrowth of intestinal Candida albicans, but the mechanisms driving this fungal bloom remain incompletely understood. We identify oxygen as a resource required for post-antibiotic C. albicans...
5.
Jenks J, Hoenigl M, Thompson G
Contemp Clin Trials Commun . 2024 Jun; 39:101310. PMID: 38832095
Background: During the early stages of the coronavirus disease 2019 (COVID-19) pandemic, those with severe COVID-19 infection were at risk for a number of opportunistic infections including COVID-19-associated pulmonary aspergillosis...
6.
Young J, Andes D, Ardura M, Arrieta A, Bow E, Chandrasekar P, et al.
Open Forum Infect Dis . 2024 Mar; 11(3):ofae082. PMID: 38481428
The epidemiology of invasive aspergillosis (IA) is evolving. To define the patient groups who will most likely benefit from primary or secondary prophylaxis, particularly those whose medical conditions and IA...
7.
Spec A, Thompson G, Miceli M, Hayes J, Proia L, McKinsey D, et al.
Open Forum Infect Dis . 2024 Mar; 11(3):ofae010. PMID: 38440302
Background: Invasive fungal disease caused by dimorphic fungi is associated with significant morbidity and mortality. Super-bioavailability itraconazole (SUBA-itra) is a novel antifungal agent with pharmacokinetic advantages over currently available formulations....
8.
Heidari A, Kaur S, Pearson S, Munoz A, Sandhu H, Mann G, et al.
Open Forum Infect Dis . 2024 Feb; 11(2):ofad679. PMID: 38370292
Background: Severe coccidioidomycosis presenting with respiratory failure is an uncommon manifestation of disease. Current knowledge of this condition is limited to case reports and small case series. Methods: A retrospective...
9.
Ferguson A, Thompson G, Bruyette D, Sykes J
Med Mycol . 2023 Dec; 62(1). PMID: 38148116
Coccidioidomycosis is a potentially fatal fungal disease of humans and animals that follows inhalation of Coccidioides spp. arthroconidia in the environment. The disease in dogs resembles that in people, and...
10.
Jenks J, Prattes J, Wurster S, Sprute R, Seidel D, Oliverio M, et al.
EClinicalMedicine . 2023 Dec; 66:102325. PMID: 38053535
Disparities in social determinants of health (SDOH) play a significant role in causing health inequities globally. The physical environment, including housing and workplace environment, can increase the prevalence and spread...